A Chinese company has begun building low-priced CT scanners, which could compete in the country for sales with systems marketed by such multinational vendors as Shimadzu, GE, and Siemens. Shenyang Neu-Alpine Software has been granted permission by the
A Chinese company has begun building low-priced CT scanners, which could compete in the country for sales with systems marketed by such multinational vendors as Shimadzu, GE, and Siemens. Shenyang Neu-Alpine Software has been granted permission by the State Pharmaceutical Administration Commission to begin mass production of CT scanners, according to Comline Computer Wire. The company is believed to be the first Chinese firm manufacturing its own CT scanners, according to sources familiar with the Chinese market.
The company plans to win market share by selling its scanners at a considerable price discount compared with products marketed by importers. Neu-Alpine Software's scanners will list at $192,700, while imported machines cost around $360,000, according to Comline. The company plans to manufacture 100 CT scanners annually.
Although the company's scanners will enjoy a major price advantage, Chinese companies do not have a stellar record in producing complex medical imaging machinery. Chinese manufacturers have been competing in MRI since the early 1990s, but have not taken a substantial share of the Chinese market, according to observers.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.